These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 37588100)
1. The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials. Lin F; Yao Q; Yu B; Deng Z; Qiu J; He R Int J Clin Pract; 2023; 2023():6638089. PubMed ID: 37588100 [TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501 [TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for the Treatment of Active Thyroid Eye Disease. Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679 [TBL] [Abstract][Full Text] [Related]
4. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials. Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ Thyroid; 2024 Jul; 34(7):880-889. PubMed ID: 38824618 [No Abstract] [Full Text] [Related]
6. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison. Douglas RS; Dailey R; Subramanian PS; Barbesino G; Ugradar S; Batten R; Qadeer RA; Cameron C JAMA Ophthalmol; 2022 Apr; 140(4):328-335. PubMed ID: 35175308 [TBL] [Abstract][Full Text] [Related]
7. Teprotumumab for thyroid eye disease: early response is not required for benefit. Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas RS Eye (Lond); 2022 Jul; 36(7):1403-1408. PubMed ID: 34183792 [TBL] [Abstract][Full Text] [Related]
8. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies. Winn BJ; Kersten RC Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408 [TBL] [Abstract][Full Text] [Related]
9. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease. Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673 [TBL] [Abstract][Full Text] [Related]
11. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study. Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417 [TBL] [Abstract][Full Text] [Related]
12. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy. Tamhankar MA; Pradeep T; Chen Y; Briceño CA J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310 [TBL] [Abstract][Full Text] [Related]
13. Teprotumumab for the treatment of thyroid eye disease. Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097 [TBL] [Abstract][Full Text] [Related]
14. Improvement of asymmetric thyroid eye disease with teprotumumab. Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690 [TBL] [Abstract][Full Text] [Related]
15. Teprotumumab for Thyroid-Associated Ophthalmopathy. Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880 [TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies for the treatment of Graves' ophthalmopathy: A systematic review and meta-analysis. Fatani WA; Hamdan DM; Taher NO; Alsharef JF; Aldubi RM; Alwagdani AM; Alhothali TN; Khan ZU Saudi J Ophthalmol; 2023; 37(2):137-148. PubMed ID: 37492211 [TBL] [Abstract][Full Text] [Related]
18. Teprotumumab for the treatment of thyroid eye disease. Ju Y; Yang J Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials. Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105 [TBL] [Abstract][Full Text] [Related]
20. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Douglas RS Eye (Lond); 2019 Feb; 33(2):183-190. PubMed ID: 30575804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]